Noxopharm Ltd. · ASX:NOX
Noxopharm — ASX Small-Mid Cap Conference March 2021
22 slides from Noxopharm's conference presentation, March 2021
Slide 1: Noxopharm Limited (ASX:NOX) ASX Small-Mid Cap Conference Presentation
Noxopharm Limited (ASX:NOX) ASX SMALL-MID CAP CONFERENCE PRESENTATION March 2021 Discover Develop Dr Graham Kelly CEO and Managing Director Deliver NOXOPHARM LIMITED (ASX:NOX) 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not Although the Company believes that the expectations reflected in the forward looking statements be considered as an offer or invitation to subscribe for, or purchase any shares in NOX, or as an in
Slide 3: Aim to boost cancer treatment effectiveness via immune system
Medical advances have helped delay the progression of many forms of cancer. However, once an aggressive cancer becomes metastatic (with secondary tumours), current treatment options generally are very limited in their effectiveness Our aim is simple. To boost the effectiveness of most current forms
Slide 4: Veyonda breakthrough COLD to HOT immunotherapy drug
Veyonda® breakthrough COLD to HOT immunotherapy drug Blocks autophagy Activates immune abscopal cells responses Inhibits Increases inflammaBon trafficking of activated immune cells Source: Dana-Faber Cancer InsPtute Converts COLD tumors to HOT tumors NOXOPHARM LIMITED (ASX:NOX) 4
Slide 5: Treatment options for metastatic cancer
Treatment options for metastatic cancer Used in most cancers Limited to certain cancer types Radiotherapy Immunotherapy RadiopharmaceuPcals Chemotherapy Targeted therapies NOXOPHARM LIMITED (ASX:NOX) 5
Slide 6: Proof-of-concept being sought by NOX in different cancer treatments
Proof-of-concept being sought by NOX in 3 different cancer treatments DARRT IONIC Immunotherapy Radiotherapy Radiopharmaceuticals LuPIN Chemotherapy Targeted therapies NOXOPHARM LIMITED (ASX:NOX) 6
Slide 7: DARRT
DARRT Veyonda® + Low Dose Radiotherapy A revolutionary new treatment for solid cancer NOXOPHARM LIMITED (ASX:NOX) 7
Slide 8: DARRT Program
DARRT Program Veyonda® + Low-Dose Radiotherapy 🔴 In metastaIc cancer, radiotherapy (RT) generally applied to 1 or 2 individual tumours 🔴 Mainly used for relief of symptoms (eg pain, loss of funcIon) 🔴 No meaningful effect on paIent survival or disease progression expected with low-dose RT alone…
Slide 9: DARRT Program: Direct and Abscopal Response to Radiotherapy
DARRT Program Direct and Abscopal Response to Radiotherapy 🔴 Aim is to deliver a dose of radiation to a single tumour and to shrink or eradicate that tumour 🔴 In the overwhelming majority of cases, the effect of the radiation is restricted to the irradiated tumour 🔴 In extremely rare cases…
Slide 10: DARRT Program
DARRT Program Low-dose radiotherapy Veyonda® (NOX66) ☛ to a single lesion ☛ 21-day cycle: daily dosing for 14 days (7 ☛ external beam radiotherapy days rest) ☛ 8-30 Gy ☛ starting Day -1 ☛ 1-10 fractionated doses ☛ repeat monthly cycles (in DARRT-2) until disease progression ☛ single cycle of radioth
Slide 11: DARRT-1 Phase 1 trial
DARRT Program DARRT Direct and Abscopal DARRT-1 Phase Response 1 trial to Radiotherapy 🔴 In 10/15* men, tumours stopped growing or 26 men with end-stage prostate cancer • had stopped responding to reduced in size treatment • had metasta<c and progressive 🔴 10/16** had meaningful pain reduc=on…
Slide 12: DARRT-2 Study Design
DARRT Program DARRT-2 Study Design 🔴 Phase 1b/2a study 🔴 Differs from DARRT-1 in higher Veyonda dose and repeat cycles 🔴 MulI-naIonal 🔴 Prostate, breast, lung cancers 🔴 100-150 paIents 🔴 Abscopal responses + range of other anI-tumour responses 🔴 Commencing H2 2021 NOXOPHARM LIMITED (ASX:NOX)…
Slide 13: LuPIN
LuPIN Veyonda® + 177lutetium-PSMA-617 An exciting new treatment for prostate cancer NOXOPHARM LIMITED (ASX:NOX) 13
Slide 14: LuPIN Program
LuPIN Program Lu-PSMA-617 is a radioacQve drug injected IV and designed to deliver radiaQon to every prostate cancer cell throughout the body Acquired by NovarQs in 2018 for US$6 billion Proposed new treatment for prostate cancer once the cancer has spread widely But …… 1/3rd men have liWle or no re
Slide 15: LuPIN: Interim Data Reporting
LuPIN: Interim Data ReporIng American Society of Clinical Oncology Genitourinary Cancers Symposium Feb 11-13 2021 ANSWER: Yes, the combinaBon of Veyonda and Lu-PSMA-617 looks to be considerably more effecBve than Lu-PSMA-617 on its own (based on published Phase 2 data1) 56 men Median Overall Survival
Slide 16: LuPIN: Interim Survival Data
LuPIN: Interim Survival Data Median overall survival = time when half the patients have died and half still alive Three standard lines of drug therapy once prostate 1st line 2nd line 3rd line End-stage cancer becomes metastaBc Historical data1 ~ 4.5 months 177 Lu-PSMA-617 alone2 13.3 months 177 Lu-P
Slide 17: IONIC
IONIC Veyonda ® + nivolumab (Opdivo®) Overcoming resistance to checkpoint inhibitors NOXOPHARM LIMITED (ASX:NOX) 17
Slide 18: IONIC Study
IONIC Study Phase I/II proof-of-concept study 15 patients pre-treated 15 patients not pre-treated with Opdivo but tumours with Opdivo because cancers not responsive considered to be unresponsive All other cancer types Typically 0-3% response rate • Melanoma • Lung • Kidney • Bladder • Head & neck Ve
Slide 19: Summary
SUMMARY Both DARRT and LuPIN have provided clear evidence of proof-of-concept DARRT: Adding Veyonda to a low dose of radiotherapy not expected to do anything more than shrink a single tumour, led in men with end-stage prostate cancer to: • A halt to disease progression or be_er in 10/15 men • Confirm
Slide 20: Our commercial end-point for Veyonda
Our commercial end-point for Veyonda A number of important blockbuster (>US$1 B annual sales) drugs are losing their exclusivity over coming years. This is putting pressure on big pharma to refresh revenue streams through M&A activity Programs focusing on immuno-oncology and cell therapy remain the
Slide 21: Key metrics
Key metrics as at 12 March 2021 Market cap A$192m News Flow (next 6 months) • IONIC-1 and DARRT-2 start paBent recruitment Share price A$0.69 • COVID-19 clinical trial compleBon • Growing first-in-class drug pipeline Issued cap 278.9m shares • Pharmorage (subsidiary) progressing novel drug developmen
Slide 22: For further information
For further informa.on email: info@noxopharm.com web: www.noxopharm.com twiaer: @noxopharm Discover Develop Deliver NOXOPHARM LIMITED (ASX:NOX) 22